What is Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics is a pioneering biotechnology firm dedicated to the development of innovative stem cell therapies. At the core of its operations is the NurOwn technology platform, which utilizes autologous adult stem cells to treat debilitating neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
The company maintains a strong market position through its commitment to rigorous clinical validation, having secured Orphan Drug designation from both US and European regulatory bodies. With research and development facilities spanning North America, the Middle East, and Asia, Brainstorm operates as a global entity focused on translating complex biological research into viable, life-altering medical treatments. Its focus on autologous therapies places it at the forefront of personalized medicine, where the company continues to refine its specialized cell production processes to meet high clinical standards.
How much funding has Brainstorm Cell Therapeutics raised?
Brainstorm Cell Therapeutics has raised a total of $55.9M across 12 funding rounds:
Private Equity
$250K
Private Equity
$3.6M
Stock Offering
$5.7M
Multiple Rounds
$16.6M
Grant
$2.1M
Grant
$16M
Grant
$496K
Stock Offering
$10M
Debt
$150K
Stock/Share Issuance
$1M
Private Equity (2011): $250K with participation from Undisclosed
Private Equity (2011): $3.6M led by Barak Capital Underwriting
Stock Issuance/Offering (2012): $5.7M supported by Maxim Group LLC and Leader Underwriters Ltd
Share Placement (2014): $10.5M featuring Maxim Group LLC
Grant (2014): $5M backed by Brazilian Ministry of Health
Grant (2014): $1.1M with participation from Israel's Office of the Chief Scientist
Grant (2017): $2.1M led by Israel Innovation Authority
Grant (2017): $16M supported by California Institute of Regenerative Medicine
Grant (2019): $496K featuring National Multiple Sclerosis Society
Stock Issuance/Offering (2020): $10M backed by Abbhi Investments, LLC
Debt (2020): $150K with participation from PPP
Stock/Share Issuance (2026): $1M, investors not publicly disclosed
Key Investors in Brainstorm Cell Therapeutics
Israel Innovation Authority
A government-backed entity focused on driving technological innovation and supporting R&D initiatives across Israel's high-tech and biotech sectors.
California Institute of Regenerative Medicine
A state-funded agency dedicated to accelerating the development of stem cell treatments and cures for chronic diseases and injuries.
Maxim Group LLC
A full-service investment banking firm providing financial advisory and capital raising services to emerging growth companies in the healthcare and life sciences industries.
What's next for Brainstorm Cell Therapeutics?
With the recent injection of $1M, Brainstorm Cell Therapeutics is poised to enter a critical phase of clinical expansion and operational scaling. The strategic roadmap likely involves the advancement of its lead candidates through late-stage clinical trials, aiming to secure broader regulatory approvals and commercial viability. As the company transitions from a research-heavy entity to a more commercially oriented biotechnology leader, the focus will shift toward optimizing manufacturing capabilities and expanding its global footprint.
Investors and industry stakeholders will be closely monitoring the company's ability to translate its scientific breakthroughs into sustainable market value. The ongoing support from both public and private backers provides the necessary runway to navigate the complexities of the biotech sector, ensuring that Brainstorm remains a key player in the development of next-generation neurodegenerative treatments.
